All In Biotech

NDA 021514 · Noven Pharms INC

Daytrana

Methylphenidate · Transdermal · Central Nervous System Stimulant

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Apr 6, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

29,057

11,071 serious, 1,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION Methylphenidate Transdermal System has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate Transdermal System, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Methylphenidate Transdermal System, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout Methylphenidate Transdermal System treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see...

What it is approved for

From the label in effect Sep 25, 2025.

Methylphenidate Transdermal System (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Use The use of Methylphenidate Transdermal System is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.4 )] . Methylphenidate Transdermal System is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. ( 1 ) Limitations of Use The use of Methylphenidate Transdermal System is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.8 , 8.4 ).

Mechanism: Methylphenidate is a CNS stimulant. Its mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • DAYTRANA · METHYLPHENIDATE 20MG/9HR (2.2MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • DAYTRANA · METHYLPHENIDATE 10MG/9HR (1.1MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • DAYTRANA · METHYLPHENIDATE 30MG/9HR (3.3MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • DAYTRANA · METHYLPHENIDATE 15MG/9HR (1.6MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event6,896
  • off label use5,958
  • product quality issue5,247
  • drug ineffective2,929
  • drug administration error1,901
  • wrong technique in drug usage process1,772
  • application site erythema1,699
  • drug dose omission1,478
  • incorrect drug administration duration1,191
  • wrong technique in product usage process1,157
  • drug prescribing error1,079
  • disturbance in attention916

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200526
200649
200797
200854
200979
2010202
20111,878
20122,128
20132,081
20141,924
20151,950
20162,578
20173,505
20181,650
20191,355
20201,139
20211,236
20221,347
20231,537
20241,483
20251,544
20261,205

Recalls

42 FDA enforcement reports for this application.

  • Mar 10, 2023 · Class II · Ongoing

    Defective Delivery System: Out of specification for shear.

  • Mar 10, 2023 · Class II · Ongoing

    Defective Delivery System: Out of specification for shear.

  • Mar 10, 2023 · Class II · Ongoing

    Defective Delivery System: Out of specification for shear.

  • Mar 10, 2023 · Class II · Ongoing

    Defective Delivery System: Out of specification for shear.

  • Nov 16, 2022 · Class II · Ongoing

    Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.

  • Jun 24, 2022 · Class II · Ongoing

    Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.

  • May 6, 2022 · Class II · Ongoing

    Defective Delivery System: customer complaints exceeded respective action limits.

  • May 20, 2021 · Class II · Ongoing

    Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits.

Shortages

FDA's drug shortage list.

  • Current · updated Oct 16, 2026

    Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65). Distributed by Padagis US LLC

  • Current · updated Oct 16, 2026

    Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65). Distributed by Padagis US LLC

  • Current · updated Oct 16, 2026

    Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65). Distributed by Padagis US LLC

  • Current · updated Oct 16, 2026

    Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65). Distributed by Padagis US LLC

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Daytrana (Methylphenidate)

2024 spending

$144K

Beneficiaries

158

703 claims

Per beneficiary

$911

$6.01 per unit

View as table
YearSpending
2020$659,391
2021$751,867
2022$708,936
2023$428,541
2024$143,903

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,058 on PubMed

Sponsor: Noven Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.